Jay R. Luly, Ph.D.

Jay R. Luly, Ph.D.

President and Chief Executive OfficeratEnanta Pharmaceuticals· In proxies 2021–2025

Pay in FY2025+3% from the year before · Enanta Pharmaceuticals stock +15.5% the same year

Jay R. Luly, Ph.D. was paid $2.8M in FY2025 (Sep), up 3%. Enanta Pharmaceuticals stock rose 15.5% that year.

Pay$100 in the stock at the end of FY20 → $26
Pay is from the Summary Compensation Table of each Enanta Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Enanta PharmaceuticalsPublic company · 5 yr
    • President and Chief Executive Officer2021 – Present · 5 yrStock in role -73%
  2. The following table contains biographical information as of December 15, 2025, about the nominees for Class I directors and our current directors whose terms of office will continue after the annual meeting. The table includes information provided by the directors individually as to theirPublic company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?